CY2015038I2 - Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt - Google Patents

Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt

Info

Publication number
CY2015038I2
CY2015038I2 CY2015038C CY2015038C CY2015038I2 CY 2015038 I2 CY2015038 I2 CY 2015038I2 CY 2015038 C CY2015038 C CY 2015038C CY 2015038 C CY2015038 C CY 2015038C CY 2015038 I2 CY2015038 I2 CY 2015038I2
Authority
CY
Cyprus
Prior art keywords
inhibitors
combinations
pyrimidine containing
nnrti
containing nnrti
Prior art date
Application number
CY2015038C
Other languages
Greek (el)
English (en)
Other versions
CY2015038I1 (el
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2015038(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CY2015038I2 publication Critical patent/CY2015038I2/el
Publication of CY2015038I1 publication Critical patent/CY2015038I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY2015038C 2003-09-03 2015-10-21 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt CY2015038I1 (el)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number Publication Date
CY2015038I2 true CY2015038I2 (el) 2016-08-31
CY2015038I1 CY2015038I1 (el) 2016-08-31

Family

ID=34280181

Family Applications (5)

Application Number Title Priority Date Filing Date
CY2015040C CY2015040I1 (el) 2003-09-03 2015-10-21 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt
CY2015039C CY2015039I1 (el) 2003-09-03 2015-10-21 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt
CY2015038C CY2015038I1 (el) 2003-09-03 2015-10-21 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt
CY2016049C CY2016049I1 (el) 2003-09-03 2016-12-20 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt
CY2016048C CY2016048I1 (el) 2003-09-03 2016-12-20 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY2015040C CY2015040I1 (el) 2003-09-03 2015-10-21 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt
CY2015039C CY2015039I1 (el) 2003-09-03 2015-10-21 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY2016049C CY2016049I1 (el) 2003-09-03 2016-12-20 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt
CY2016048C CY2016048I1 (el) 2003-09-03 2016-12-20 Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt

Country Status (24)

Country Link
US (9) US20080200435A1 (enExample)
EP (1) EP1663240B2 (enExample)
JP (3) JP5507791B2 (enExample)
KR (1) KR20060090658A (enExample)
CN (1) CN101060844B (enExample)
AP (1) AP2109A (enExample)
AU (5) AU2004268390B2 (enExample)
BE (1) BE2015C053I2 (enExample)
CA (1) CA2537095C (enExample)
CY (5) CY2015040I1 (enExample)
FI (1) FI1663240T4 (enExample)
FR (5) FR15C0073I2 (enExample)
HR (1) HRP20150798T4 (enExample)
HU (5) HUS1500054I1 (enExample)
IL (2) IL173438A (enExample)
LT (2) LTPA2016045I1 (enExample)
LU (3) LU92853I2 (enExample)
MX (1) MXPA06002437A (enExample)
MY (1) MY169670A (enExample)
NL (2) NL300781I1 (enExample)
NO (6) NO334877B1 (enExample)
NZ (1) NZ545306A (enExample)
PL (1) PL1663240T5 (enExample)
WO (1) WO2005021001A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AP2296A (en) * 2004-09-02 2011-10-31 Janssen Pharmaceutica Nv Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
MX2007002595A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Clorhidrato de 4-[[4-[[4- (2-cianoetenil)-2, 6-dimetilfenil] amino]-2- pirimidinil] amino] benzonitrilo.
AP2487A (en) * 2004-09-02 2012-10-03 Janssen Pharmaceutica Nv Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
ME01617B (me) * 2006-01-20 2014-09-20 Janssen R&D Ireland Dugotrajno tretiranje hiv-infekcije s tcm278
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2234620B1 (fr) * 2008-01-03 2016-03-09 Université d'Aix-Marseille Tritherapie utilisable lors du traitement d'un patient infecte par le vih
JP5612602B2 (ja) * 2008-12-24 2014-10-22 ヤンセン・アールアンドデイ・アイルランド Ｈｉｖ処置用の移植可能デバイス
AU2010338425B2 (en) 2009-12-21 2015-07-23 Janssen Sciences Ireland Uc Degradable removable implant for the sustained release of an active compound
PT3494972T (pt) 2010-01-27 2024-02-12 Viiv Healthcare Co Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
CA2818097C (en) * 2010-11-19 2019-07-30 Janssen R & D Ireland Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
CA2848631C (en) * 2011-09-16 2019-10-01 Hetero Research Foundation Rilpivirine hydrochloride
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2948021C (en) 2015-11-09 2024-06-18 Gilead Sciences, Inc. Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
KR20190073450A (ko) 2016-10-24 2019-06-26 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 분산성 조성물
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
JP2020517633A (ja) * 2017-04-18 2020-06-18 シプラ・リミテッド レトロウイルス感染の治療に用いる併用療法
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
CN115397422A (zh) 2019-11-29 2022-11-25 西皮欧生命科学有限公司 包含利匹韦林的组合物和其用于治疗肿瘤或癌症的用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
DE69122478T2 (de) 1990-07-19 1997-05-28 Otsuka Pharma Co Ltd Feste zusammensetzung
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
ATE184787T1 (de) 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
CN1174741C (zh) 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
KR20030011805A (ko) 2000-03-30 2003-02-11 브리스톨-마이어스스퀴브컴파니 스타부딘을 함유하는 서방성 비들렛
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
ES2333645T3 (es) 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
EP1458361A4 (en) 2001-11-20 2007-04-25 Advanced Inhalation Res Inc COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT
CN102702111B (zh) 2002-08-09 2014-12-17 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
DE60313657T2 (de) 2002-11-08 2008-01-03 Smithkline Beecham Corp. Antivirale zusammensetzungen
AU2003296760B2 (en) 2002-11-15 2009-11-19 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN1747937A (zh) 2003-02-07 2006-03-15 詹森药业有限公司 预防hiv感染的嘧啶衍生物
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
EP1765283A4 (en) 2004-06-08 2012-11-28 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2007002595A (es) 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Clorhidrato de 4-[[4-[[4- (2-cianoetenil)-2, 6-dimetilfenil] amino]-2- pirimidinil] amino] benzonitrilo.
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
EP1827374B1 (en) 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
JP2008538754A (ja) * 2005-04-11 2008-11-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 薬剤を含んだ所定のレイヤパターンを有する複層構造体
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
JP2009502969A (ja) 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド 非晶質エファビレンツ及びその製造
ME01617B (me) 2006-01-20 2014-09-20 Janssen R&D Ireland Dugotrajno tretiranje hiv-infekcije s tcm278
SG173315A1 (en) 2006-06-23 2011-08-29 Tibotec Pharm Ltd Aqueous suspensions of tmc278
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
SI2175857T1 (sl) 2007-07-12 2014-01-31 Janssen R&D Ireland Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
WO2010047819A1 (en) * 2008-10-24 2010-04-29 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives

Also Published As

Publication number Publication date
PL1663240T5 (pl) 2024-02-26
AU2019200813A1 (en) 2019-02-28
LU92855I2 (fr) 2015-12-21
IL213104A (en) 2016-02-29
AU2016210733A1 (en) 2016-08-25
NO2014031I1 (no) 2015-01-05
FI1663240T4 (fi) 2023-04-25
AU2016210733B2 (en) 2018-11-08
NO2014031I2 (no) 2014-12-18
LU92853I2 (fr) 2015-12-21
AU2014203484B2 (en) 2016-09-29
FR15C0073I1 (enExample) 2015-04-12
FR15C0071I1 (enExample) 2015-04-12
US8841310B2 (en) 2014-09-23
CY2016049I2 (el) 2017-07-12
EP1663240B1 (en) 2015-04-22
IL173438A (en) 2012-03-29
US20190216807A1 (en) 2019-07-18
CY2016048I2 (el) 2017-07-12
US20150283135A1 (en) 2015-10-08
HRP20150798T1 (hr) 2015-09-11
NL300781I2 (enExample) 2016-04-19
US20080200435A1 (en) 2008-08-21
HUS1500052I1 (hu) 2016-03-29
MY169670A (en) 2019-05-08
US20170100398A1 (en) 2017-04-13
FR16C1022I1 (fr) 2017-02-03
HUS1600058I1 (hu) 2017-02-28
JP2012051915A (ja) 2012-03-15
IL213104A0 (en) 2011-07-31
AU2004268390A1 (en) 2005-03-10
AP2109A (en) 2010-02-26
CY2016049I1 (el) 2017-07-12
AU2014203484A1 (en) 2014-07-17
NL300768I2 (nl) 2023-08-09
FR16C1024I1 (fr) 2017-02-03
CY2015039I2 (el) 2016-08-31
CN101060844A (zh) 2007-10-24
EP1663240B2 (en) 2023-03-01
HUS1500054I1 (hu) 2016-03-29
CY2015040I2 (el) 2016-08-31
LTPA2016045I1 (lt) 2017-01-10
FR15C0072I2 (fr) 2019-05-17
MXPA06002437A (es) 2006-06-20
AP2006003551A0 (en) 2006-04-30
JP5507791B2 (ja) 2014-05-28
HK1092698A1 (en) 2007-02-16
NZ545306A (en) 2009-11-27
LU92854I2 (fr) 2015-12-21
JP2007520443A (ja) 2007-07-26
CY2015040I1 (el) 2016-08-31
CA2537095C (en) 2012-05-29
NO2014030I2 (no) 2014-12-18
JP2015044839A (ja) 2015-03-12
CY2016048I1 (el) 2017-07-12
NL300781I1 (enExample) 2016-04-19
AU2011201123B2 (en) 2013-10-10
WO2005021001A1 (en) 2005-03-10
AU2004268390B2 (en) 2011-03-31
LTPA2016044I1 (lt) 2017-01-10
CY2015039I1 (el) 2016-08-31
PL1663240T3 (pl) 2015-10-30
US20140349971A1 (en) 2014-11-27
CN101060844B (zh) 2012-01-04
AU2011201123A1 (en) 2011-04-07
NO2014032I1 (no) 2015-01-05
US20220008417A1 (en) 2022-01-13
FR15C0072I1 (enExample) 2015-04-12
NO2014030I1 (no) 2015-01-05
FR15C0073I2 (fr) 2016-02-12
HUS1600059I1 (hu) 2017-02-28
FR15C0071I2 (fr) 2016-02-12
LTC1663240I2 (lt) 2022-05-25
NO2014032I2 (no) 2014-12-18
NO334877B1 (no) 2014-06-23
EP1663240A1 (en) 2006-06-07
US20180228800A1 (en) 2018-08-16
US20200171027A1 (en) 2020-06-04
JP5820045B2 (ja) 2015-11-24
HRP20150798T4 (hr) 2023-06-09
CA2537095A1 (en) 2005-03-10
NO2016026I1 (no) 2016-12-20
NO20061374L (no) 2006-03-27
NL300768I1 (enExample) 2015-12-16
CY2015038I1 (el) 2016-08-31
US20100029591A1 (en) 2010-02-04
KR20060090658A (ko) 2006-08-14
NO2016025I1 (enExample) 2016-12-20
BE2015C053I2 (enExample) 2023-12-14
IL173438A0 (en) 2006-06-11
HUS1500053I1 (hu) 2016-03-29

Similar Documents

Publication Publication Date Title
CY2016048I1 (el) Συνδυασμοι μιας πυριμιδινης που περιεχουν nnrti με αναστολεις rt
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1745052T3 (da) HIV-intergrase-inhibitorer: cykliske pyrimidinonforbindelser
IS7599A (is) Heterósýklískir kínasatálmar
ATE529412T1 (de) Herbizide pyrimidine
DK1761505T3 (da) Pyrimidin-urinstof-derivater som kinaseinhibitorer
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
EP1667683A4 (en) QUINOLINE POTASSIUM CHANNEL INHIBITORS
ATE520672T1 (de) Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
DE602005002033D1 (de) Verdampfen von temperaturempfindlichen materialien für oled
ATE370124T1 (de) Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
ATE512960T1 (de) Pyrimidinderivate
ITMI20021391A1 (it) Nitroderivati di inibitori della cicloossigenasi-2
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
EP1697331A4 (en) INHIBITORS OF MITOTIC KINESINE
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
EP1697381A4 (en) INHIBITORS OF MITOTIC KINESINE
TWI365744B (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
DK1432452T3 (da) Inhibering af STAT-1